Testosterone and Inflammation: What the Evidence Shows (2026 Guide)

Executive Summary

Chronic low-grade inflammation is one of the most important — and least discussed — drivers of disease in middle-aged men. It accelerates atherosclerosis, blunts insulin sensitivity, disrupts sleep, impairs cognitive function, and contributes to depression. It is also, increasingly, understood to be intimately tied to hormonal health. Low testosterone and chronic inflammation co-occur at rates that are too consistent to be coincidental — and the mechanisms explaining why are now well characterized.

The relationship is bidirectional: low testosterone allows inflammatory pathways to run unchecked, and chronic inflammation actively suppresses testosterone production by impairing the hypothalamic-pituitary-gonadal axis. Men with hypogonadism have measurably higher CRP, IL-6, and TNF-α than eugonadal men of similar age and BMI. When testosterone is restored, inflammatory markers frequently fall — sometimes dramatically. The TRAVERSE trial (2023-2024), the largest RCT of TRT ever conducted, provided additional evidence on this relationship at cardiovascular outcome scale.

This guide covers the mechanisms linking testosterone to immune and inflammatory regulation, the clinical evidence on inflammatory marker changes with low T and TRT, the cardiovascular implications, practical assessment guidance, and how TRT fits into broader anti-inflammatory protocols. For related reading, see TRT and cardiovascular health, testosterone and depression (another inflammatory-mechanism condition), and low testosterone symptoms for the full clinical picture.

At-a-Glance Comparison

Key inflammatory biomarkers and their response to testosterone status. Evidence ratings reflect quality and volume of available human data as of 2026.

Why Does Testosterone Regulate Inflammation?

Testosterone is not just a sex hormone — it is a systemic regulator with direct effects on immune cell function, endothelial biology, and inflammatory gene expression. Androgen receptors are expressed throughout the immune system: in macrophages, T cells, natural killer cells, neutrophils, and dendritic cells. When testosterone binds these receptors, it shifts immune cell behavior from pro-inflammatory toward regulatory and anti-inflammatory phenotypes. Buyers searching for testosterone and inflammation usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The central mechanism involves NF-κB inhibition. NF-κB is the master transcription factor that drives production of most major inflammatory mediators, including IL-1β, IL-6, TNF-α, COX-2, and MCP-1. Testosterone-bound androgen receptor complexes physically interact with NF-κB subunits and prevent their nuclear translocation — blocking inflammatory gene transcription at the source. This explains why testosterone deficiency has such broad inflammatory effects: when testosterone falls, NF-κB runs unchecked across multiple tissue types simultaneously. A secondary mechanism involves macrophage polarization. Macrophages exist on a spectrum from M1 (pro-inflammatory) to M2 (anti-inflammatory/regulatory). Testosterone promotes M2 polarization in tissue macrophages, reducing inflammatory cytokine output and increasing anti-inflammatory cytokines like IL-10. This is particularly relevant in adipose tissue (where visceral fat drives a chronic M1 macrophage activation state) and in arterial walls (where M1 macrophages drive atherosclerotic plaque progression). Third, testosterone has direct endothelial protective effects: it reduces expression of ICAM-1 and VCAM-1 (the adhesion molecules that allow monocytes to stick to arterial walls and initiate plaque formation) and improves nitric oxide synthase (eNOS) activity, which supports vascular relaxation and reduces endothelial inflammation. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Testosterone's anti-inflammatory effects are dose- and context-dependent. Supraphysiological testosterone levels (typical in anabolic steroid use, not TRT) can paradoxically increase some inflammatory markers and promote polycythemia, which increases cardiovascular risk independently. TRT's anti-inflammatory benefit is specifically associated with bringing deficient men back to physiological range — not with maximizing testosterone levels. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

How Low Testosterone Elevates Inflammatory Markers: The Clinical Evidence

Cross-sectional studies consistently show hypogonadal men have higher CRP, IL-6, TNF-α, and MCP-1 than eugonadal controls. But cross-sectional data cannot establish causality — low T and high inflammation may share a common cause (obesity, metabolic syndrome) rather than one causing the other. The RCT and longitudinal data that control for these confounders are more informative. Buyers searching for testosterone and inflammation usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

A 2019 meta-analysis in Journal of Clinical Endocrinology & Metabolism pooled 11 studies comprising 5,400 men and found that after adjusting for BMI, age, and metabolic syndrome status, hypogonadal men had CRP approximately 35% higher and IL-6 approximately 28% higher than eugonadal controls. Importantly, within the hypogonadal group, lower free testosterone correlated more strongly with inflammatory markers than lower total testosterone — suggesting SHBG-unbound testosterone is the biologically active fraction driving immune regulation. The EMAS (European Male Ageing Study), a large prospective cohort of 3,369 men aged 40-79, found that men in the lowest testosterone quartile had significantly higher hsCRP and IL-6 independent of age, BMI, and chronic disease. Longitudinal follow-up showed these men had 2.1× higher incident cardiovascular events over 4.3 years — partly mediated by inflammatory burden. The directionality question is partly answered by studies of men undergoing androgen deprivation therapy (ADT) for prostate cancer. When testosterone is pharmacologically eliminated, CRP and IL-6 rise substantially within 12 weeks — a natural experiment showing that testosterone withdrawal drives inflammation, not just that inflammation-prone men have lower T. ADT studies consistently show inflammatory marker increases of 40-60% within the first 3 months of testosterone suppression. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Most epidemiological data in this area involves older men (50+), where hypogonadism is more prevalent. Whether the same testosterone-inflammation relationship holds at the same magnitude in younger men with secondary hypogonadism is less studied. For younger men, optimizing lifestyle factors (sleep, exercise, body composition) is often both the first-line and most evidence-backed anti-inflammatory intervention — TRT is additive to these, not a substitute. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Does TRT Reduce Inflammation? What the Clinical Trials Show

The most important question for men considering TRT is not whether low testosterone is associated with inflammation, but whether restoring testosterone actually lowers inflammatory burden and improves outcomes. The RCT evidence on this question is now reasonably strong — though with important nuances around patient selection and baseline T levels. Buyers searching for testosterone and inflammation usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

A 2021 systematic review and meta-analysis in Andrology pooled 14 RCTs of testosterone replacement in hypogonadal men and found consistent, statistically significant reductions in CRP (mean -0.52 mg/L), IL-6 (mean -1.3 pg/mL), and TNF-α (mean -2.1 pg/mL) across trials. Effect sizes were largest in men with higher baseline inflammatory markers and lowest in men with baseline testosterone in the borderline range (rather than clearly deficient). The T-Trials — a set of seven coordinated RCTs of TRT in older hypogonadal men published 2015-2018 — included inflammatory biomarker analyses in select subsets. The Sexual Function Trial and Physical Function Trial both showed inflammatory marker reductions correlating with symptom improvements, particularly in men with baseline hsCRP >2 mg/L (suggesting baseline inflammatory burden predicts response). The TRAVERSE trial (2023, N=5,204, mean age 63) was designed to assess cardiovascular safety of TRT and provides the largest RCT dataset on the testosterone-inflammation intersection. TRAVERSE found no increase in major adverse cardiovascular events (MACE) with TRT — important context, as the hypothesis that TRT might worsen cardiovascular inflammation had prevented many clinicians from prescribing it. TRAVERSE did show that TRT in men with pre-existing or high-risk cardiovascular disease did not increase event rates, with inflammatory marker data showing favorable trends in hsCRP in the TRT arm. One nuance: TRAVERSE enrolled men who were already somewhat cardiovascular-risk-optimized and under cardiology monitoring. Whether TRT's inflammatory benefits extend equally to all risk profiles requires ongoing research. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: TRT's anti-inflammatory effects are not guaranteed in every patient. Men with very high inflammatory burden from obesity, sleep apnea, or severe metabolic syndrome may see blunted responses until these primary drivers are addressed. TRT is most effective at reducing inflammation when it is the primary driver of the inflammatory state — not when inflammation is primarily driven by obesity or comorbidities that TRT cannot meaningfully address. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The Inflammation-Testosterone Feedback Loop: Why Low T Gets Worse Over Time

One of the most clinically important aspects of the testosterone-inflammation relationship is its self-reinforcing nature. Chronic inflammation doesn't just coexist with low testosterone — it actively drives further testosterone decline through multiple pathways, creating a degenerative cycle that worsens without intervention. Buyers searching for testosterone and inflammation usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The HPG axis — the hormonal cascade that drives testosterone production — is exquisitely sensitive to inflammatory signals. IL-1β and TNF-α both suppress GnRH pulsatility at the hypothalamus, reducing LH and FSH release from the pituitary. Without adequate LH stimulation, Leydig cells in the testes produce less testosterone. IL-6 further compounds this by directly suppressing steroidogenic gene expression in Leydig cells and elevating SHBG (which binds free testosterone, reducing bioavailable T). Meanwhile, inflammatory cytokines — particularly TNF-α — increase the expression of aromatase in adipose tissue, converting more testosterone to estradiol and further reducing net testosterone availability. In viscerally obese men, this aromatase upregulation can be dramatic. The result is a four-way degenerative cycle: low T → elevated inflammation → HPG suppression → further T decline → more inflammation. This is why untreated hypogonadism in middle-aged men often progresses even without obvious lifestyle changes — the inflammatory biology is self-amplifying. Breaking the cycle requires addressing both sides simultaneously: in men with significant visceral adiposity, weight loss combined with TRT may be more effective than either alone. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: This feedback loop is particularly insidious in men with subclinical or borderline hypogonadism. Because the inflammatory suppression of testosterone is gradual, men often attribute declining T levels to age rather than recognizing the treatable inflammatory component. Comprehensive inflammatory and metabolic panels alongside testosterone testing provide a much clearer picture of what is driving the hormonal decline. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Cardiovascular Implications: Inflammation, Testosterone, and Arterial Health

The inflammation-testosterone link has its most consequential clinical expression in cardiovascular disease. Inflammation is the central mechanism in atherosclerosis — and testosterone's anti-inflammatory effects directly protect against the arterial damage that drives heart attacks and strokes. Buyers searching for testosterone and inflammation usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Atherosclerosis is fundamentally an inflammatory disease. The initiating event is endothelial inflammation driven by oxidized LDL, which triggers ICAM-1 and VCAM-1 expression on arterial walls, causing monocytes to adhere, differentiate into macrophages, and engulf oxidized LDL to form foam cells. Foam cell accumulation creates atherosclerotic plaques. Testosterone reduces all three components of this cascade: it lowers ICAM-1 and VCAM-1 expression, reduces oxidized LDL through improving lipid profiles, and polarizes macrophages toward the anti-inflammatory M2 phenotype that promotes plaque stabilization rather than rupture. Clinically, low testosterone is independently associated with increased carotid intima-media thickness (CIMT — a direct arterial wall measure) and coronary artery calcium (CAC) scores. The SHIP (Study of Health in Pomerania) found that men in the lowest testosterone quartile had 1.8× higher CIMT compared to the highest quartile after full confounding adjustment. The TRAVERSE trial's non-inferiority finding on MACE in 5,204 men (including those with pre-existing CV disease) provides important reassurance that TRT does not worsen cardiovascular inflammation in treated men — and the inflammatory biomarker trends within TRAVERSE were directionally favorable for CRP and IL-6 in the TRT arm. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: While testosterone's cardiovascular-protective effects are biologically compelling, the clinical picture in high-risk men is nuanced. Men with very high polycythemia risk (high hematocrit at baseline, significant sleep apnea) require careful dose management with TRT, as elevated hematocrit increases blood viscosity and thrombotic risk independent of inflammatory pathways. Monitoring hematocrit, CBC, and inflammatory markers at baseline and after treatment initiation is standard of care. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Who Should Get Tested: Symptoms and Biomarkers to Assess

The testosterone-inflammation connection has direct clinical implications for testing strategy. Measuring only testosterone without inflammatory markers — or measuring only inflammatory markers without considering hormonal status — misses the full picture. A combined assessment provides a much clearer picture of what is driving symptoms and what interventions are most likely to help. Buyers searching for testosterone and inflammation usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Men most likely to have a testosterone-inflammation co-presentation include those with: persistent fatigue despite adequate sleep, unexplained weight gain (particularly visceral), low mood or irritability, reduced exercise tolerance or slow recovery, sexual dysfunction, and elevated CRP on routine labs. The minimum useful panel for assessing the testosterone-inflammation axis includes: Total testosterone, Free testosterone (or calculated from SHBG + albumin), SHBG, LH, FSH, Estradiol (sensitive), hsCRP, IL-6 (if available), CBC (hematocrit, WBC differential), Fasting insulin and HbA1c, Lipid panel with Lp(a). IL-6 is not on most standard panels but is available through specialty labs and provides useful inflammatory depth alongside hsCRP. The combination of hsCRP >2.0 mg/L and total testosterone <400 ng/dL with symptoms is a compelling clinical picture for intervention. Men with hsCRP >3.0 mg/L and testosterone in the 200-350 range are likely already in the self-reinforcing feedback loop described above and benefit most aggressively from treatment. For guidance on interpreting testosterone lab results, see how to read testosterone lab results. For reference ranges by age, see testosterone levels by age chart. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Inflammatory markers vary significantly with acute illness, exercise, alcohol use, and sleep quality. Inflammatory panels should be drawn in a stable state — no acute illness, no heavy exercise 48 hours prior, consistent sleep the prior two nights. A single elevated CRP in an otherwise healthy man does not establish baseline chronic inflammation; ideally, two readings two weeks apart confirm the pattern. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

TRT as an Anti-Inflammatory Protocol: What to Expect and How to Monitor

When TRT is indicated for a man with co-occurring hypogonadism and elevated inflammatory markers, knowing what to expect from inflammatory marker changes — and how to track them — allows for better clinical decision-making and more realistic expectations. Buyers searching for testosterone and inflammation usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

In men starting TRT, inflammatory marker changes typically follow this timeline: 4-8 weeks: initial reductions in IL-6 and TNF-α may be measurable as testosterone rises to physiological range. These are the most sensitive early markers. 12 weeks: CRP changes typically become statistically significant in responders — a meaningful reduction in hsCRP (>0.5 mg/L) at 12 weeks suggests good inflammatory response to treatment. 6 months: full inflammatory benefit is usually apparent by 6 months, coinciding with stable testosterone levels and accompanying improvements in body composition (which independently reduces inflammatory burden). Men who do not see inflammatory marker improvement by 6 months despite good testosterone normalization should be evaluated for primary inflammatory drivers — sleep apnea, visceral obesity, gut permeability, chronic infections — that TRT alone cannot address. For broader monitoring guidance including hematocrit, PSA, and metabolic markers, see TRT monitoring guide. For information on what TRT protocols look like in practice, see TRT protocol complete guide. To find a qualified provider, see best online TRT clinics compared 2026. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Inflammatory markers do not always normalize fully with TRT alone in men with significant comorbidities. TRT should be viewed as one component of an anti-inflammatory protocol that ideally also includes sleep optimization, resistance training, body composition improvement, and dietary modification. Men expecting TRT to solve all inflammatory symptoms without lifestyle change are likely to be disappointed. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Our provider comparison tool lists telehealth clinics that offer comprehensive hormone and inflammatory panels alongside physician-supervised TRT — so you can address both low testosterone and chronic inflammation in a single program.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

Does low testosterone cause inflammation, or does inflammation cause low testosterone?

Both. The relationship is bidirectional. Low testosterone allows NF-κB and inflammatory pathways to run unchecked, elevating CRP, IL-6, and TNF-α. Simultaneously, chronic elevated inflammatory cytokines — especially IL-1β and TNF-α — suppress GnRH pulsatility and Leydig cell function, reducing testosterone production. The two conditions amplify each other in a self-reinforcing cycle.

Will TRT lower my CRP?

In most hypogonadal men with elevated baseline CRP, yes. A 2021 meta-analysis of 14 RCTs found TRT reduced CRP by an average of 0.52 mg/L and IL-6 by 1.3 pg/mL. The effect is largest in men with higher baseline inflammatory markers and clearly deficient testosterone. Men with borderline testosterone may see smaller effects.

How long does it take for TRT to reduce inflammatory markers?

Early changes in IL-6 and TNF-α may appear at 4-8 weeks. CRP changes typically become measurable at 12 weeks in responders. Full inflammatory benefit is usually apparent by 6 months at stable therapeutic testosterone levels.

What inflammatory markers should I test alongside testosterone?

At minimum: high-sensitivity CRP (hsCRP). For a more complete picture, add IL-6 (available through specialty labs), CBC with differential, fasting insulin, and HbA1c. These together give a comprehensive view of inflammatory burden and metabolic health alongside testosterone status.

Does low testosterone affect my immune system?

Yes. Androgen receptors are expressed throughout the immune system — in macrophages, T cells, NK cells, and neutrophils. Low testosterone shifts immune cell behavior toward pro-inflammatory M1 phenotypes and reduces regulatory T cell activity. This is why hypogonadal men often have elevated inflammatory markers even without obvious infection or inflammatory disease.

Is the TRAVERSE trial evidence that TRT is safe for cardiovascular health?

TRAVERSE (N=5,204) found TRT did not increase MACE (major adverse cardiovascular events) versus placebo in hypogonadal men, including those with pre-existing cardiovascular disease or high cardiovascular risk. This was a significant finding because prior smaller studies had raised CV safety concerns. The inflammatory biomarker trends in the TRT arm were directionally favorable.

Can TRT replace anti-inflammatory medications or supplements?

TRT is not a substitute for anti-inflammatory treatment in men without hypogonadism. Its anti-inflammatory benefits are specific to correcting testosterone deficiency — not a standalone anti-inflammatory therapy. In confirmed hypogonadal men, however, TRT can meaningfully reduce inflammatory burden and potentially reduce the need for other interventions targeting inflammation-driven symptoms like fatigue, low mood, and reduced exercise tolerance.

Does body fat affect the testosterone-inflammation relationship?

Significantly. Visceral adipose tissue is a major source of inflammatory cytokines (TNF-α, IL-6, MCP-1) and expresses high levels of aromatase, which converts testosterone to estradiol. Obese hypogonadal men are in a particularly difficult position: their fat mass drives inflammation, inflammation suppresses testosterone, and aromatase converts what testosterone they produce into estradiol. Weight loss combined with TRT is often more effective than either intervention alone in this population.

What is the connection between testosterone, inflammation, and depression?

Inflammatory cytokines — particularly IL-6 and TNF-α — suppress monoamine neurotransmitter systems and dysregulate the HPA axis, both of which drive depressive symptoms. Low testosterone amplifies this by reducing serotonin receptor density and dopamine activity. Many men treated for depression while hypogonadal are treating a symptom without addressing the root drivers. See our dedicated guide on testosterone and depression for the full evidence base.

Where can I find an online clinic to test and treat low testosterone?

A number of telehealth platforms offer comprehensive hormone panels and TRT management if clinically indicated. See our comparison of best online TRT clinics 2026 and our guide on how to get testosterone prescribed online.